These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19721197)

  • 1. [Relationship between insulin resistance and bone metabolism].
    Hamada Y
    Clin Calcium; 2009 Sep; 19(9):1269-74. PubMed ID: 19721197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Overview: derangement of bone metabolism in diabetes mellitus].
    Takeuchi Y
    Clin Calcium; 2009 Sep; 19(9):1247-55. PubMed ID: 19721195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Do thiazolidinediones harm skeletal integrity?].
    Takeuchi Y
    Clin Calcium; 2008 May; 18(5):650-5. PubMed ID: 18445884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
    Patsouris D; Müller M; Kersten S
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Peroxisome proliferator activated receptors (PPAR) and insulin sensitivity: experimental studies].
    Haluzík MM; Haluzík M
    Cesk Fysiol; 2006; 55(4):163-8. PubMed ID: 17685022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
    Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
    Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the antidiabetic agent pioglitazone on bone metabolism in rats.
    Kanda J; Izumo N; Kobayashi Y; Onodera K; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
    J Pharmacol Sci; 2017 Sep; 135(1):22-28. PubMed ID: 28928054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
    Heald M; Cawthorne MA
    Handb Exp Pharmacol; 2011; (203):35-51. PubMed ID: 21484566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of PPARs and their isoforms in metabolic disorders related to insulin resistance and diabetes].
    Kravchenko NA; Iarmysh NV
    Tsitol Genet; 2011; 45(3):68-78. PubMed ID: 21774406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of thiazolidinediones on bone loss and fracture.
    Murphy CE; Rodgers PT
    Ann Pharmacother; 2007 Dec; 41(12):2014-8. PubMed ID: 17940125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PPARs as molecular targets for drug discovery].
    Kagechika H; Miyachi H
    Nihon Rinsho; 2005 Apr; 63(4):549-55. PubMed ID: 15828219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G; Torres N; Tovar AR
    Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology.
    Scatena R; Bottoni P; Martorana GE; Vincenzoni F; Botta G; Pastore P; Giardina B
    Eur J Pharmacol; 2007 Jul; 567(1-2):50-8. PubMed ID: 17499714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.